Fig. 2From: First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancerWaterfall plot of the best overall response. The bars indicate the largest percentage change in target lesions from baseline. The colors represent different best tumor response. The lower horizontal dashed line indicates a 30% reduction from baseline. The upper horizontal dashed line indicates a 20% increase from baselineBack to article page